Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Insights into the Regulatory Properties of Human Adenylyl Cyclase Type 9

Tanya A. Baldwin, Yong Li, Cameron S. Brand, Val J. Watts and Carmen W. Dessauer
Molecular Pharmacology April 2019, 95 (4) 349-360; DOI: https://doi.org/10.1124/mol.118.114595
Tanya A. Baldwin
Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas (T.A.B., Y.L., C.S.B., C.W.D.); and Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana (V.J.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tanya A. Baldwin
Yong Li
Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas (T.A.B., Y.L., C.S.B., C.W.D.); and Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana (V.J.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cameron S. Brand
Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas (T.A.B., Y.L., C.S.B., C.W.D.); and Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana (V.J.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Val J. Watts
Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas (T.A.B., Y.L., C.S.B., C.W.D.); and Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana (V.J.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen W. Dessauer
Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, Texas (T.A.B., Y.L., C.S.B., C.W.D.); and Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana (V.J.W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    AC9 is conditionally activated by forskolin. (A) Western blot using α-FLAG (top) and goat α-AC9 (bottom) for membranes from Sf9 cells expressing vector control (β-gal) or human AC9. (B and C) Dose-response curves of Gαs stimulation of AC9 and β-gal Sf9 membranes in the presence or absence of 50 µM forskolin (Fsk) (B) and membranes from HEK293 cells expressing AC9 in the presence or absence of 100 µM forskolin (C) [activity from control membranes (D) was subtracted]. The inset in (B) shows individual replicates for 3 µM Gαs with or without forskolin. (D) AC activity of membranes isolated from HEK293 cells expressing pcDNA3 (background AC activity). Data are shown as means ± S.D. Statistical analyses in (B) through (D) were performed with two-way ANOVA followed by the Sidak multiple-comparisons test of experimental means comparing vehicle and forskolin-stimulated groups at each concentration indicated. n = 3 to 4 with experiments performed in duplicate. *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    AC9 is less sensitive to Gαs compared with AC6 and is insensitive to Gβγ. (A) Dose-response curves of Gαs stimulation of membranes from Sf9 cells expressing AC9, AC6, or β-gal. (B) Dose-response curves of Gαs stimulation of Sf9 membranes expressing AC9 or β-gal in the presence and absence of 100 nM Gβ1γ2. Data are shown as means ± S.D. Statistical analyses in (B) were performed with two-way ANOVA followed by a Sidak multiple-comparisons test comparing experimental means of vehicle- and Gαs- or Gβ1γ2-stimulated groups at each concentration indicated. n = 3. No statistical difference was found in the presence of Gβγ.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    AC9 is not directly regulated by Gαi/o in vitro. (A) Structure-based alignment of amino acids that correspond to the Gαi binding site in AC5. (B) Gαs dose-response curves for AC9 and β-gal Sf9 membranes in the presence and absence of 300 nM Gαi. (C) Gαi dose-response curves for AC9 and β-gal Sf9 membranes in the presence of 300 nM Gαs. (D) E. coli vs. Sf9 purified Gαi isoforms. AC9 Sf9 membranes were stimulated with 300 nM Gαs in the presence or absence of 300 nM Gαi1 (E. coli or Sf9) or Gαi3. (E) AC6 membranes with 50 nM Gαs ± 300 nM Gαi proteins served as a positive control. (F) Gαo regulation of AC9 Sf9 membranes stimulated with 300 nM Gαs. (G) AC1 membranes stimulated with 100μM Ca2+/300 nM CaM with 1 μM Gαo served as a positive control. Data are shown as means ± S.D. Statistical analyses were performed as follows: (B) and (D), two-way ANOVA followed by a Sidak multiple-comparisons test comparing the vehicle and Gαi/o groups at each concentration indicated; (C), (E), and (F), one-way ANOVA followed by a Tukey multiple-comparisons test comparing experimental means; and (G), t test comparing Ca2+/CaM with or without Gαo. For all experiments, n = 3 to 4, performed in duplicate or triplicate. *P < 0.05; **P < 0.01; ***P < 0.001. No statistical difference was found for Gαi/o under any condition with AC9 (B–D and F). ns, not significant.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Neither CaMKII nor PKCβII directly regulates AC9. (A) AC9 membranes were stimulated with 100 nM Gαs in the presence or absence of 200 µM Ca2+/1 µM calmodulin (Ca2+/CaM), 100 ng CaMKII, or Ca2+/CaM plus CaMKII. The inset shows 32P labeling of MBP by CaMKII, performed in duplicate. As a positive control, AC3 was stimulated with 100 nM Gαs in the presence of 200 µM Ca2+/1 µM CaM in the presence or absence of 100 ng CaMKII. (B) AC2, AC9, and β-gal membranes were stimulated with 100 nM Gαs in the presence or absence of 1 µM PMA or PMA plus purified PKCβII. The inset shows 32P labeling of MBP by PKCβII, performed in duplicate. Data are shown as means ± S.D. Statistical analyses were performed as follows: (A), two-way ANOVA followed by a Sidak multiple-comparisons test; (B), a paired t test comparing the control and the kinase group; and (C), one-way ANOVA followed by a Tukey multiple-comparisons test. For all experiments, n = 3, performed in duplicate. *P < 0.05; **P < 0.01. ns, not significant.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Regulation of endogenous and overexpressed AC9 in COS-7 cells. (A) Representative traces of cells expressing μOR with or without AC6 or AC9 treated with 1 µM isoproterenol (ISO; black square) ± 10 μM DAMGO. Arrows indicate the addition of drugs (ISO/DAMGO). (B) Quantitation of individual cell traces. Data points were averaged (avg) from the 12- to 14-minute timepoints of ISO (1 µM) and ISO plus 10 μM DAMGO. (C) Western blot of COS-7 whole-cell lysates, confirming expression of endogenous or exogenous AC9 (top: rabbit anti-AC9) and AC6 (bottom). (D) Confirmation of endogenous AC9 protein by Western blot of membranes isolated from COS-7 cells, or cells expressing an AC9 siRNA or control siRNA. The Na-K ATPase served as a loading control for COS-7 membranes. Data are shown as means ± S.D. Statistical analyses in (B) were performed with two-way ANOVA followed by a Sidak multiple-comparisons test comparing ISO and ISO plus DAMGO. n = 3–5 with experiments performed in duplicate. **P < 0.01. au, arbitrary unit; KD, knockdown; ns, not significant.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Basal AC activity is dependent on AC9 in COS-7 cells and mouse splenocytes. (A) AC assay of membranes from COS-7 cells stably expressing control or AC9 shRNA/siRNA stimulated with 400 nM Gαs or 50 µM forskolin. (B) Whole-cell basal cAMP accumulation was measured in COS-7 cells expressing control shRNA, AC9 shRNA, or overexpressing (OVE) AC9 using a GloSensor bioluminescent cAMP reporter. Cells were pretreated with 1 mM IBMX for 10 minutes. (C) Quantitative real-time PCR of AC isoforms present in spleen from AC9−/− mice, normalized to wild-type (WT) expression levels (n = 3). (D) AC assay of WT and AC9 knockout (KO) spleen membranes stimulated with 400 nM Gαs or 50 µM forskolin in the presence or absence of the P-site inhibitor, Ara-A (300 nM). (E and F) Whole-cell cAMP accumulation of mouse splenocytes isolated from WT and AC9KO mice treated with 1 mM IBMX ± 1 μM ISO. Data are shown as means ± S.D. Statistical analysis were performed as follows: (A) and (D), two-way ANOVA followed by a Sidak multiple-comparison test [comparisons within Ara-A treatments in (D) were made separately]; (B), (E), and (F), an unpaired t test of means comparing the indicated groups; and (C), one-way ANOVA followed by a Tukey multiple-comparisons test. For all, experiments were performed in duplicate. n = 3 to 4. *P < 0.05; **P < 0.01; ***P < 0.001. KO, knockout; ns, not significant.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    AC9 homo- and heterodimers. Quantification of COS-7 cells expressing BiFC constructs for AC9, AC5, and AC6. One of two halves of a fluorescent protein: the N-terminal portion (VN) or the C-terminal portion (VC) is fused in frame to the C terminus of each AC isoform, except where noted. (A) The homodimers are expressing both AC-VN and AC-VC for the given isoform. AC9-VN alone is a negative control. (B) Heterodimer formation used AC-VN (top one listed) from one isoform with AC-VC from a second isoform. For example, AC5-AC9 corresponds to cotransfection of AC5-VN and AC9-VC. AC5* is N-terminally tagged with VC. (C and D) Cell extracts from cells transiently transfected with Flag-AC9 (fAC9) with or without AC5 (C) or Flag-AC9 with or without AC6 (D) were subjected to immunoprecipitation with FLAG-agarose and Western blotted for FLAG, AC5, or AC6. As positive controls, Flag-AC5 and YFP-AC6 were immunoprecipitated with FLAG-agarose or anti-GFP and protein G. The delta symbol indicates a nonspecific band; no endogenous AC6 is ever observed in pulldowns of Flag-AC9. Note, although the FLAG tag on the control Flag-AC5 can be used for immunoprecipitation, it is not readily detected by Western blotting. Data are shown as means ± S.D. Statistical analyses in (A) and (B) were performed with one-way ANOVA followed by the Dunnet multiple-comparisons test comparing AC9 VN to each condition indicated. n = 3–5 with experiments performed in duplicate. *P < 0.05; **P < 0.01; ***P < 0.001. GFP, green fluorescent protein; ns, not significant.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 95 (4)
Molecular Pharmacology
Vol. 95, Issue 4
1 Apr 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Insights into the Regulatory Properties of Human Adenylyl Cyclase Type 9
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Direct Regulation of AC9

Tanya A. Baldwin, Yong Li, Cameron S. Brand, Val J. Watts and Carmen W. Dessauer
Molecular Pharmacology April 1, 2019, 95 (4) 349-360; DOI: https://doi.org/10.1124/mol.118.114595

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Direct Regulation of AC9

Tanya A. Baldwin, Yong Li, Cameron S. Brand, Val J. Watts and Carmen W. Dessauer
Molecular Pharmacology April 1, 2019, 95 (4) 349-360; DOI: https://doi.org/10.1124/mol.118.114595
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics